Crizanlizumab

N/A

Report date: 2026/03/20 20:03:07
First In Class

Base Information

Drug NameCrizanlizumab
Drug Alias NameCrizanlizumab-tmcaAdakveoRyvernaSel-G-1SEG-101 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionP-selectin inhibitors
TargetsP-selectin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Primary MyelofibrosisAnemia, Sickle Cell +[5] 
Global Approved IndicationsAnemia, Sickle Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/11/15
Country/TerritoryBelgiumCanadaPanama +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSelexys Pharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineNovartis Pharma AgNovartis Pharmaceuticals Corp
Inactive CompaniesReprixys Pharmaceutical CoJohns Hopkins UniversityNovartis Europharm Ltd
Active IndicationsAnemia, Sickle CellPriapismLeukoencephalopathies
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Primary Myelofibrosis

Other Information

ATC CodeB06AX01
Related LinksWikipediaDrugBankKEGG